Jeannette Hanna, MD
Psychiatry · Huntington Beach, CANPI 1578652798
Payments from drug & device makers
Across 1,085 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $10K from 28 others
What the payments were for
- Food & beverage$23,69399%
- Education$1621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 249 | $4,286 |
| Johnson & Johnson | 73 | $2,300 |
| Teva Pharmaceuticals USA, Inc. | 99 | $2,070 |
| Otsuka America Pharmaceutical, Inc. | 76 | $2,006 |
| Neurocrine Biosciences, Inc. | 57 | $1,654 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $1,512 |
| Lundbeck LLC | 73 | $1,374 |
| Vanda Pharmaceuticals Inc. | 49 | $1,312 |
| Sunovion Pharmaceuticals Inc. | 37 | $1,079 |
| Alkermes, Inc. | 29 | $950 |
| Corium, LLC | 42 | $875 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $827 |
| Ironshore Pharmaceuticals Inc. | 29 | $549 |
| Supernus Pharmaceuticals, Inc. | 18 | $462 |
| Axsome Therapeutics, Inc. | 19 | $443 |
| Tris Pharma Inc | 18 | $405 |
| Indivior Inc. | 13 | $292 |
| Noven Therapeutics, LLC | 14 | $277 |
| Adlon Therapeutics L.p. | 15 | $235 |
| Neos Therapeutics, LP | 8 | $185 |
| Biogen | 4 | $107 |
| Collegium Pharmaceutical, Inc. | 5 | $103 |
| Bausch Health US, LLC | 5 | $97 |
| Almatica Pharma LLC | 3 | $79 |
| Braeburn Inc. | 3 | $77 |
| Avanir Pharmaceuticals, Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Neuronetics, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $24 |
| Merck | 1 | $18 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$601
- REXULTI$593
- LYBALVI$500
- LATUDA$473
- ARISTADA$472
- SPRAVATO$442
- INGREZZA$362
- QELBREE$132
- Jornay PM 20mg capsules (Bottle of 100)$129
- Fanapt$125
- Dyanavel XR$121
- UZEDY$120
- ARISTADA INITIO$118
- AUSTEDO$114
How this compares
$23,855 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $98,443 |
| VraylarCariprazine Hcl | 62 | $92,233 |
| RexultiBrexpiprazole | 22 | $32,066 |
| TrintellixVortioxetine Hydrobromide | 63 | $30,896 |
| CaplytaLumateperone Tosylate | 12 | $19,394 |
| FetzimaLevomilnacipran Hcl | 18 | $13,209 |
| QelbreeViloxazine Hcl | 20 | $8,939 |
| Aripiprazole | 60 | $8,921 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,750 |
| Quetiapine Fumarate | 74 | $1,120 |
| Fluvoxamine Maleate | 19 | $959 |
| Bupropion XlBupropion Hcl | 27 | $499 |
| Duloxetine Hcl | 28 | $483 |
| Vilazodone Hcl | 12 | $459 |
| Clonazepam | 26 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $4,286 | $105,44280 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,070 | $98,44313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $827 | $36,64676 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,006 | $32,06622 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,512 | $19,39412 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $462 | $8,93920 claims |
| Almatica Pharma LLCSertraline Hcl | $79 | $16015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Huntington Beach
- Steven MacinaHuntington Beach$11.1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.